DC Chemicals Limited
China
Product Name: KY-05009
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

1228280-29-2

1228280-29-2 structure

Name: KY-05009
Chemical Name: 2-Anilino-5-[(4-methylbenzoyl)amino]-1,3-thiazole-4-carboxamide
CAS Number: 1228280-29-2
Molecular Formula: C₁₈H₁₆N₄O₂S
Molecular Weight: 352.410
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2018-06-04 17:14:35
Modify Date: 2024-01-06 18:44:23
KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a Ki of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity[1].

Name	2-Anilino-5-[(4-methylbenzoyl)amino]-1,3-thiazole-4-carboxamide
Synonyms	MFCD29059915 4-Thiazolecarboxamide, 5-[(4-methylbenzoyl)amino]-2-(phenylamino)- 2-Anilino-5-[(4-methylbenzoyl)amino]-1,3-thiazole-4-carboxamide KY-05009

Description	KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a Ki of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity[1].
Related Catalog	Signaling Pathways >> MAPK/ERK Pathway >> MAP4K Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> Stem Cell/Wnt >> Wnt
Target	TNIK:100 nM (Ki)
In Vitro	KY-05009 (0.1-30 μM; 24 hours; RPMI8226 cells) treatment inhibits the proliferation of RPMI8226 cells in a dose-dependent manner[1]. KY-05009 (1-3 μM; 48-72 hours; RPMI8226 cells) treatment induces caspase-dependent apoptosis in RPMI8226 cells in a dose-dependent manner[1]. KY-05009 (3 μM; 1 hour; RPMI8226 cells) treatment suppresses the transcriptional activity of Wnt signaling-related genes, including TNIK, CTNNB1, TCF7, and TCF4[1]. .KY-05009 (3 μM; 9 hours; RPMI8226 cells) treatment inhibits the IL-6-induced interaction between TCF4 and β-catenin and the phosphorylation of TCF4[1]. Cell Proliferation Assay[1] Cell Line: RPMI8226 cells Concentration: 0.1 μM, 0.3 μM, 1 μM, 3 μM, 10 μM, 30 μM Incubation Time: 24 hours Result: Inhibited the proliferation of RPMI8226 cells. Apoptosis Analysis[1] Cell Line: RPMI8226 cells Concentration: 1 μM, 3 μM, 10 μM Incubation Time: 48 hours, 72 hours Result: Induced the binding of fluorescent Annexin V and 7-amino-actinomycin D (7-AAD) uptake. RT-PCR[1] Cell Line: RPMI8226 cells Concentration: 3 μM Incubation Time: 1 hour Result: Suppressed the transcriptional activity of Wnt signaling-related genes, including TNIK, CTNNB1, TCF7, and TCF4. Western Blot Analysis[1] Cell Line: RPMI8226 cells Concentration: 3 μM Incubation Time: 9 hours Result: The IL-6-induced interaction between TCF4 and β-catenin and the phosphorylation of TCF4 were inhibited.
References	[1]. Lee Y, et al. Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells. Oncotarget. 2017 Jun 20;8(25):41091-41101.

Density	1.4±0.1 g/cm3
Molecular Formula	C₁₈H₁₆N₄O₂S
Molecular Weight	352.410
Exact Mass	352.099396
LogP	2.83
Index of Refraction	1.728

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302
Precautionary Statements	P301 + P312 + P330
RIDADR	NONH for all modes of transport

1228280-29-2	1621673-53-7
2093406-88-1	2093407-25-9
1223284-75-0	2489390-15-8
468056-29-3	110816-78-9
92602-21-6	172544-75-1